Medical Oncology

Cleveland Clinic

Questions discussed in this category

What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?

Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...

1 Answer available

How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?

How do you choose between CAR-T and autoSCT, for example?

3 Answers available

How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?

1 Answer available

What is your approach in a fit patient, advanced stage, bulky classical Hodgkin lymphoma who has decreased disease burden in areas but a persistent, hypermetabolic (Deauville 5) anterior mediastinal mass following two cycles of AAVD?

2 Answers available

How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?

1 Answer available

How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?

Ki67 = 90% with multiple small nodes on PET scan and normal CBC

1 Answer available

What treatment regimen would you recommend for young adults with platinum refractory relapsed germ cell tumors?

2 Answers available

Papers discussed in this category

Ann Oncol, 2007 Nov 15

Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Outcome of deferred initial therapy in mantle-cell lymphoma.

The New England journal of medicine, 2015-11-05

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Haematologica, 2018 May 24

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.

Blood,

p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.

Leukemia, 2011 Jul 01

Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.

Haematologica, 2019 Sep 19

mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.

Blood, 2017 Aug 17

mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.

Blood, 2015 May 28

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.

British journal of haematology, 2017-11

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.

J Clin Oncol, 2016 Feb 29

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Lancet Haematol, 2016 Dec 05

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Lancet Oncol, 2022 Jan 21

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

N Engl J Med,

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

N Engl J Med, 2022 Dec 11

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

J Clin Oncol, 2022 Dec 22

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Blood Adv, 2022 May 10

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.

Blood, 2022 Dec 15

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.

J Clin Oncol, 2021 Jun 25

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.

Lancet (London, England), 2019-01-19

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Blood, 2022 Mar 03

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

Lancet,

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

N Engl J Med, 2021 Dec 11

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Medical Oncology

Cleveland Clinic

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology